| scholarly article | Q13442814 |
| P2093 | author name string | Sagie Schif-Zuck | |
| Gizi Wildbaum | |||
| Nathan Karin | |||
| Gila Maor | |||
| Izhar Salomon | |||
| Nir Netzer | |||
| P2860 | cites work | DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA. | Q38305300 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2685-2693 | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. | |
| P478 | volume | 169 |
| Q44403847 | An antibody to IP-10 is a potent antagonist of cell migration in vitro and in vivo and does not affect disease in several animal models of inflammation |
| Q79291232 | Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity |
| Q38666452 | Biased signaling pathways via CXCR3 control the development and function of CD4+ T cell subsets |
| Q53275429 | CCR8+FOXp3+ Treg cells as master drivers of immune regulation. |
| Q28569526 | CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis |
| Q41621932 | CXCL10 induces the recruitment of monocyte-derived macrophages into kidney, which aggravate puromycin aminonucleoside nephrosis |
| Q35220391 | CXCL10/gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice |
| Q37726647 | CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. |
| Q36946584 | CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells |
| Q36677670 | CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. |
| Q34726782 | CXCR3 in T cell function |
| Q37827339 | CXCR3 ligands: redundant, collaborative and antagonistic functions |
| Q24803773 | CXCR3/CXCL10 expression in the synovium of children with juvenile idiopathic arthritis |
| Q37188336 | Celastrus treatment modulates antigen-induced gene expression in lymphoid cells of arthritic rats |
| Q79994185 | Chemokine and chemokine receptor analysis reveals elevated interferon-inducible protein-10 (IP)-10/CXCL10 levels and increased number of CCR5+ and CXCR3+ CD4 T cells in synovial fluid of patients with enthesitis-related arthritis (ERA) |
| Q48020890 | Chemokine production during hypersensitivity pneumonitis |
| Q38994830 | Chemokine receptor CXCR3 deficiency exacerbates murine autoimmune cholangitis by promoting pathogenic CD8+ T cell activation |
| Q36063483 | Chemokines and their receptors in rheumatoid arthritis: future targets? |
| Q35553416 | Chemokines in joint disease: the key to inflammation? |
| Q36955305 | Cia5d regulates a new fibroblast-like synoviocyte invasion-associated gene expression signature. |
| Q34456715 | Cytokine-modulating strategies and newer cytokine targets for arthritis therapy |
| Q54664669 | Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. |
| Q36925396 | Experimental coronavirus retinopathy (ECOR): retinal degeneration susceptible mice have an augmented interferon and chemokine (CXCL9, CXCL10) response early after virus infection |
| Q35792171 | Expression Analysis of the T-Cell-Targeting Chemokines CXCL9 and CXCL10 in Mice and Humans with Endothelial Infections Caused by Rickettsiae of the Spotted Fever Group |
| Q36434847 | Functional diversity of chemokines and chemokine receptors in response to viral infection of the central nervous system. |
| Q24797400 | High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis |
| Q52956228 | Human dendritic cells respond to Porphyromonas gingivalis LPS by promoting a Th2 effector response in vitro |
| Q37432097 | International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors |
| Q54539589 | Involvement of retinoic acid-inducible gene-I in inflammation of rheumatoid fibroblast-like synoviocytes. |
| Q38445448 | Ligand-biased and probe-dependent modulation of chemokine receptor CXCR3 signaling by negative allosteric modulators. |
| Q36283431 | Liver X receptor regulates rheumatoid arthritis fibroblast-like synoviocyte invasiveness, matrix metalloproteinase 2 activation, interleukin-6 and CXCL10. |
| Q37953766 | MAOS and medicinal chemistry: some important examples from the last years. |
| Q35942439 | Manipulating the type 1 vs type 2 balance in type 1 diabetes |
| Q36859581 | Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors |
| Q35164728 | Potential new drugs for therapy of chronic obstructive pulmonary disease |
| Q35684207 | Prolonged tumor necrosis factor α primes fibroblast-like synoviocytes in a gene-specific manner by altering chromatin. |
| Q35953412 | Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines |
| Q90642824 | Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis |
| Q36253492 | Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines |
| Q36150612 | Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis |
| Q35802958 | Technologies for enhanced efficacy of DNA vaccines |
| Q35570427 | Th1 immune response promotes severe bone resorption caused by Porphyromonas gingivalis |
| Q35568430 | The Role of Chemokines in Inflammatory Skin Diseases |
| Q26773127 | The Role of Chemokines in Shaping the Balance Between CD4(+) T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer Diseases |
| Q37760665 | The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease |
| Q33892454 | Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse. |
| Q35144038 | Therapeutic vaccination to block receptor-ligand interactions |
| Q35134646 | VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools |
Search more.